Breaking News

AGC Biologics, AdaptVac Partner to Develop COVID-19 Vaccine

Will leverage AdaptVac's Virus-Like Particle (VLP) technology that could provide a solution to protect against new SARS-CoV-2 infections.

By: Contract Pharma

Contract Pharma Staff

AGC Biologics, a biopharmaceutical CDMO, is partnering with AdaptVac to develop and produce a COVID-19 vaccine. AdaptVac, together with its EU Horizon 2020 PREVENT-nCoV consortium partners, are developing a SARS-CoV-2 vaccine leveraging AdaptVac’s Virus-Like Particle (VLP) technology with potential to protect against new SARS-CoV-2 infections. AdaptVac’s technology allows the rapid development of a COVID-19 vaccine to begin clinical trials in late 2020. Virus-Like Particles (VLPs)...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters